Are there any right rules for the sequence of treatment for chemotherapy for breast cancer patients?

Are there any right rules for the sequence of treatment for chemotherapy for breast cancer patients?

VJOncology

3 years
344 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Pierfranco Conte, MD of the University of Padova, Padova, Italy talks about his side of the debate on whether or not there are any correct rules for the sequence treatment of chemotherapy at the 2016 World Congress on Controversies in Breast Cancer (CoBrCa) in Barcelona, Spain. Prof. Conte explains that he believes there are no right rules for the sequence of treatment for chemotherapy for advanced breast cancer. There are however some general and generally accepted rules. One of these is that in case of hormone receptor-positive disease you should prefer an endocrine therapy in front-line and only switch to chemotherapy in the case of endocrine resistance. The second rule is that if you have to administer chemotherapy, sequential single agent chemotherapy is better because it is more tolerable and combination chemotherapy should be reserved only for patients with high tumor burden and life-threatening disease. Apart from these two rules it is hard to say there is a right sequence of cytotoxic drugs. He says that the sequence must be customised according to the patients characteristics and the choice must be made after looking at the history of the patient, the desire of the patient and the physical condition of the patient.
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
3 Views
Cancer-News 2 days
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
26 Views
Cancer-News 3 days
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 3 days
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 3 days
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 3 days
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
4 Views
kidneycancer 4 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
5 Views
Cancer-News 4 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 4 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
11 Views
kidneycancer 5 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
4 Views
Cancer-News 5 days